GAD65 is the antibody test most closely associated with LADA, and for most people, it’s the only one that comes up. But it isn’t the only autoimmune marker autoimmune diabetes produces, and it isn’t always the one that turns positive first. Four antibody tests, plus one older test still used in some labs, make up the fuller picture.
The other markers
- IA-2 (insulinoma-associated antigen 2) targets a different protein in the same insulin-producing beta cells. It’s more strongly associated with classic, fast-progressing Type 1 diabetes than with LADA, but it does show up in a minority of LADA cases.
- ZnT8 (zinc transporter 8) is a newer addition to the standard panel, added specifically because some people who test negative for GAD65 and IA-2 turn out positive for ZnT8. Including it catches autoimmune cases the older two-test panel would have missed.
- ICA (islet cell antibodies) is the oldest of these tests, measured by looking for antibody binding across a whole slice of pancreatic tissue under a microscope rather than testing for one specific protein. It’s less standardized between labs than the others and has largely been supplemented by the more specific tests above, though some labs still run it.
- IAA (insulin autoantibodies) targets insulin itself. It’s most useful before someone has ever taken insulin as a medication, since injected insulin can trigger antibodies that make the test impossible to interpret afterward. For most adults diagnosed with LADA, by the time testing happens this one is often no longer usable.
Why GAD65 is usually the one that matters
In LADA specifically, GAD65 is positive far more often than any of the others. Multiple studies on adult-onset autoimmune diabetes put GAD65 positivity around 90% of LADA cases, while IA-2 and ZnT8 positivity each show up in a much smaller share. That’s part of why GAD65 became the default first test: it’s the one most likely to catch LADA on its own.
Classic childhood-onset Type 1 diabetes tends to look different. It’s common there to see multiple antibodies positive at once, and the number of positive antibodies is itself informative: more positive markers generally means a faster path toward complete insulin dependence.
Does a diagnosis need more than one positive result?
No. The widely used clinical criteria for LADA, from the Immunology of Diabetes Society, require only one positive islet autoantibody (most commonly GAD65), alongside adult onset and no insulin requirement for at least six months after diagnosis. A single positive GAD65 result, in that context, is sufficient to identify LADA. Additional antibody tests aren’t a requirement for the diagnosis itself.
Where the other tests earn their place is in two narrower situations:
- GAD65 comes back negative, but the clinical picture still looks like LADA. A Type 2 diagnosis that doesn’t fit the usual profile, medication that’s failing faster than expected, none of that goes away just because one antibody test was negative. Testing IA-2 or ZnT8 next can catch the smaller share of cases GAD65 alone would miss.
- Understanding likely progression, not confirming the diagnosis. For someone already GAD65-positive, a doctor may still check IA-2 or ZnT8 to get a fuller sense of how aggressively the autoimmune process might progress, since multiple positive antibodies are associated with a shorter timeline to insulin dependence. This is a prognosis question, not a diagnostic one.
Where to go from here
If you’re GAD65-positive already, GAD65 Antibodies Explained covers what that result means on its own and how it’s usually read alongside a C-peptide test. If you’re GAD65-negative but the rest of the picture still points toward LADA, that’s worth raising directly with your doctor as a reason to test further, not a reason to rule LADA out.
This page is educational, not medical advice. Which tests are worth running, and what a given combination of results means for you, is a conversation for your own doctor.